

10/816,700

=> file caplus

FILE 'CAPLUS' ENTERED AT 16:44:07 ON 26 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Jul 2007 VOL 147 ISS 5

FILE LAST UPDATED: 25 Jul 2007 (20070725/ED)


Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d que

L1

STR



Structure attributes must be viewed using STN Express query preparation.

L3 10 SEA FILE=REGISTRY SSS FUL L1

L4 2 SEA FILE=CAPLUS L3

=> d l4 1-2 ibib abs hitstr

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:857171 CAPLUS

DOCUMENT NUMBER: 141:332223

TITLE: Preparation of heterocyclic bicyclic compounds as NR2B receptor antagonists

INVENTOR(S): Ando, Kazuo; Kawai, Makoto; Kawamura, Mitsuhiro; Matsumizu, Miyako; Morita, Asato; Sakurada, Isao

PATENT ASSIGNEE(S): Pfizer Japan, Inc., Japan

SOURCE: U.S. Pat. Appl. Publ., 36 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004204409	A1	20041014	US 2004-816700	20040402

CA 2521907 A1 20041021 CA 2004-2521907 20040401
 WO 2004089366 A1 20041021 WO 2004-IB1177 20040401
 WO 2004089366 A8 20051027

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW


RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1615636 A1 20060118 EP 2004-725125 20040401
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

BR 2004009241 A 20060328 BR 2004-9241 20040401
 JP 2006522794 T 20061005 JP 2006-506485 20040401

PRIORITY APPLN. INFO.: US 2003-461918P P 20030410
 WO 2004-IB1177 W 20040401

OTHER SOURCE(S): CASREACT 141:332223; MARPAT 141:332223
 GI



AB Title compds. I [R1-2 = H, halo, alkyl, alkoxy, etc.; X = bond, alkylene, etc.; A = bicyclic, aromatic, (un)saturated heterocyclic ring, etc.; B = Ph, heteroaryl, etc.] are prepared For instance, N-[(2-benzyl-1H-indol-5-yl)methyl]-4-hydroxybenzamide (II) is prepared in 2 steps from (2-benzyl-1H-indol-5-yl)carbonitrile. II has $K_i = 2$ nM for the NR2B receptor. I is useful for the treatment of disease conditions caused by over activation of NMDA NR2B receptor, e.g., pain.


IT 773883-79-7P 773883-80-0P 773883-81-1P
 773883-91-3P 773883-95-7P 773883-97-9P
 773883-98-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic bicyclic compds. as NR2B receptor antagonists for the treatment of, e.g., pain)

RN 773883-79-7 CAPLUS


CN Benzamide, 4-hydroxy-N-[[2-(phenylmethyl)-1H-benzimidazol-5-yl]methyl]-(9CI) (CA INDEX NAME)



RN 773883-80-0 CAPLUS


10/816,700

CN Benzamide, 4-hydroxy-N-[[2-(2-phenylethyl)-1H-benzimidazol-5-yl]methyl]-
(9CI) (CA INDEX NAME)




RN 773883-81-1 CAPLUS

CN Benzamide, 4-hydroxy-N-[[2-(hydroxyphenylmethyl)-1H-benzimidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 773883-91-3 CAPLUS

CN Benzamide, N-[[2,3-dihydro-2-oxo-3-(2-phenylethyl)-1H-benzimidazol-5-yl]methyl]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 773883-95-7 CAPLUS

CN Benzamide, N-[[2-[(2-fluorophenyl)methyl]-1H-benzimidazol-5-yl]methyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 773883-97-9 CAPLUS


CN Benzamide, 4-hydroxy-N-[[2-methyl-1-(2-phenylethyl)-1H-benzimidazol-6-yl]methyl]- (9CI) (CA INDEX NAME)



10/816,700

RN 773883-98-0 CAPLUS

CN Benzamide, 3-fluoro-4-hydroxy-N-[[2-(phenylmethyl)-1H-benzimidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)




IT 773884-10-9P 773884-11-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterocyclic bicyclic compds. as NR2B receptor antagonists for the treatment of, e.g., pain)


RN 773884-10-9 CAPLUS

CN Benzamide, 4-hydroxy-N-[[2-(2-phenyl-1,3-dioxolan-2-yl)-1H-benzimidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 773884-11-0 CAPLUS

CN Benzamide, N-[(2-benzoyl-1H-benzimidazol-5-yl)methyl]-4-hydroxy- (9CI). (CA INDEX NAME)



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:747806 CAPLUS

DOCUMENT NUMBER: 135:273164

TITLE: Preparation of O-glucoside benzamides as antidiabetic agents and SGLT2 inhibitors

INVENTOR(S): Washburn, William N.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074835	A1	20011011	WO 2001-US10093	20010329
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

10/816,700

CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 2002052326 A1 20020502 US 2001-791186 20010223
US 6555519 B2 20030429
CA 2404376 A1 20011011 CA 2001-2404376 20010329
EP 1268503 A1 20030102 EP 2001-922841 20010329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004500417 T 20040108 JP 2001-572524 20010329
PRIORITY APPLN. INFO.: US 2000-193308P P 20000330
WO 2001-US10093 W 20010329
OTHER SOURCE(S): MARPAT 135:273164
GI



I



II

AB Glycosides. I wherein n is 0-2; A is substituted aryl or heteroaryl which may contain 1 to 4 heteroatoms in the ring which may be selected from N, O, S, SO, and/or SO₂; R1 is H, alkoxy, alkyl, aryl, arylalkyl, amide, amine, halogen; were prepared as SGLT2 inhibiting agents. A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with one, two or more other antidiabetic agents and/or one, two or more hypolipidemic agents. Thus, glycoside II was prepared as antidiabetic and hypolipidemic agent and SGLT2 inhibitor (no data).

IT 363136-19-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

10/816,700


study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of O-glucoside benzamides as antidiabetic agents and SGLT2 inhibitors)

RN 363136-19-0 CAPLUS

CN Benzamide, N-(1H-benzimidazol-5-ylmethyl)-2-(β -D-glucopyranosyloxy)-6-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => file uspatall

FILE 'USPATFULL' ENTERED AT 16:44:47 ON 26 JUL 2007.

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


FILE 'USPAT2' ENTERED AT 16:44:47 ON 26 JUL 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> d que

L1

STR



Structure attributes must be viewed using STN Express query preparation.

L3 10 SEA FILE=REGISTRY SSS FUL L1

L5 3 SEA L3

=> d l5 1-3 ibib abs hitstr

L5 ANSWER 1 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2004:261907 USPATFULL

TITLE: Bicyclic compounds as NR2B receptor antagonists

INVENTOR(S): Ando, Kazuo, Aichi-ken, JAPAN

Kawai, Makoto, Aichi-ken, JAPAN
 Kawamura, Mitsuhiro, Aichi-ken, JAPAN
 Matsumizu, Miyako, Aichi-ken, JAPAN
 Morita, Asato, Aichi-ken, JAPAN
 Sakurada, Isao, Aichi-ken, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004204409	A1	20041014
APPLICATION INFO.:	US 2004-816700	A1	20040402 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-461918P	20030410 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WARNER-LAMBERT COMPANY, 2800 PLYMOUTH RD, ANN ARBOR, MI, 48105	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3057	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a compound of the formula (I): ##STR1##

wherein R.sup.1 and R.sup.2 independently represent a hydrogen atom or the like; X represents a covalent bond or the like: A represents a bicyclic, aromatic, saturated or partially unsaturated heterocyclic or carbocyclic group having from 8 to 12 ring atoms; or the like: B represents a phenyl group or a heteroaryl group having from 5 to 6 ring atoms or the like:

These compounds are useful for the treatment of disease conditions caused by overactivation of NMDA NR2B receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 773883-79-7P 773883-80-0P 773883-81-1P
 773883-91-3P 773883-95-7P 773883-97-9P
 773883-98-0P

(preparation of heterocyclic bicyclic compds. as NR2B receptor antagonists for the treatment of, e.g., pain)

RN 773883-79-7 USPTFLL


CN Benzamide, 4-hydroxy-N-[[2-(phenylmethyl)-1H-benzimidazol-5-yl]methyl]-(9CI) (CA INDEX NAME)



RN 773883-80-0 USPTFLL


CN Benzamide, 4-hydroxy-N-[[2-(2-phenylethyl)-1H-benzimidazol-5-yl]methyl]-(9CI) (CA INDEX NAME)

10/816,700




RN 773883-81-1 USPATFULL

CN Benzamide, 4-hydroxy-N-[[2-(hydroxyphenylmethyl)-1H-benzimidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 773883-91-3 USPATFULL

CN Benzamide, N-[[2,3-dihydro-2-oxo-3-(2-phenylethyl)-1H-benzimidazol-5-yl]methyl]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 773883-95-7 USPATFULL

CN Benzamide, N-[[2-[(2-fluorophenyl)methyl]-1H-benzimidazol-5-yl]methyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 773883-97-9 USPATFULL


CN Benzamide, 4-hydroxy-N-[[2-methyl-1-(2-phenylethyl)-1H-benzimidazol-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 773883-98-0 USPATFULL

CN Benzamide, 3-fluoro-4-hydroxy-N-[[2-(phenylmethyl)-1H-benzimidazol-5-yl]methyl]- (9CI) (CA INDEX NAME)

10/816,700




IT 773884-10-9P 773884-11-0P

(preparation of heterocyclic bicyclic compds. as NR2B receptor antagonists for the treatment of, e.g., pain)


RN 773884-10-9 USPATFULL

CN Benzamide, 4-hydroxy-N-[[2-(2-phenyl-1,3-dioxolan-2-yl)-1H-benzimidazol-5-yl)methyl]- (9CI) (CA INDEX NAME)



RN 773884-11-0 USPATFULL

CN Benzamide, N-[(2-benzoyl-1H-benzimidazol-5-yl)methyl]-4-hydroxy- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2002:99425 USPATFULL

TITLE: O-glucosylated benzamide SGLT2 inhibitors and method

INVENTOR(S): Washburn, William N., Titusville, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002052326	A1	20020502
	US 6555519	B2	20030429
APPLICATION INFO.:	US 2001-791186	A1	20010223 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-193308P	20000330 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MARLA J MATHIAS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1420	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	SGLT2 inhibiting compounds are provided having the formula ##STR1##	

10/816,700

wherein

n is 0, 1 or 2;

A is ##STR2##

or heteroaryl which may contain 1 to 4 heteroatoms in the ring which may be selected from N, O, S, SO, and/or SO.sub.2, bearing substituents R.sup.3 and R.sup.4;

and R.sup.1 to R.sup.4 are as defined herein.

A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with one, two or more other antidiabetic agents and/or one, two or more hypolipidemic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 363136-19-0P

(preparation of O-glucoside benzamides as antidiabetic agents and SGLT2 inhibitors)

RN 363136-19-0 USPATFULL

CN Benzamide, N-(1H-benzimidazol-5-ylmethyl)-2-(β-D-glucopyranosyloxy)-6-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 3 OF 3 USPAT2 on STN

ACCESSION NUMBER: 2002:99425 USPAT2

TITLE: O-glucosylated benzamide SGLT2 inhibitors and method

INVENTOR(S): Washburn, William N., Titusville, NJ, United States

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6555519	B2	20030429
APPLICATION INFO.:	US 2001-791186		20010223 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-193308P	20000330 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Henley, III, Raymond	

10/816,700

LEGAL REPRESENTATIVE: Kilcoyne, John M., Provoost, Jonathan N.

NUMBER OF CLAIMS: 24

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT: 1334

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB SGLT2 inhibiting compounds are provided having the formula ##STR1##

wherein

n is 0, 1 or 2;

A is ##STR2##

or heteroaryl which may contain 1 to 4 heteroatoms in the ring which may be selected from N, O, S, SO, and/or SO.sub.2, bearing substituents R.sup.3 and R.sup.4;

and R.sup.1 to R.sup.4 are as defined herein.

A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with one, two or more other antidiabetic agents and/or one, two or more hypolipidemic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 363136-19-0P

(preparation of O-glucoside benzamides as antidiabetic agents and SGLT2 inhibitors)

RN 363136-19-0 USPAT2

CN Benzamide, N-(1H-benzimidazol-5-ylmethyl)-2-(β -D-glucopyranosyloxy)-6-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>